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was initiated. The remainder of the patients (n = 62) received ACE inhibitors and ARBs as before. Patients were followed every 3 months for 18 months. During each visit, systolic and diastolic blood pressure (BP), urinary albumin excretion (UAE), serum creatinine, estimated glomerular filtration rate (eGFR) and serum potassium concentrations were determined. Results. After 18 months, three patients in the SPR/ARB group developed asymptomatic hyperkalemia. SPR/ARB significantly reduced both systolic and diastolic BP (P < 0.001 and 0.001, respectively). SPR/ARB decreased UAE by 46, 72 and 59% after 3, 12 and 18 months, respectively. Compared with the continuation regimen, SPR/ARB was superior in UAE reduction (P = 0.017 after 18 months), independent of BP change. In both groups, eGFR declined significantly over the trial course and the decline rate did not differ significantly between the two groups. Conclusions. Addition of SPR to ARB provides added benefits with respect to BP control and proteinuria diminution. These antiproteinuric effects are not accompanied by prevention of eGFR loss compared with conventional therapy with ACE/ARB.
I N T R O D U C T I O N
The burden of diabetic nephropathy is staggering-consuming a large proportion of health resources [1, 2] . A recent costof-illness study from Iran revealed that diabetic nephropathy accounts for 23% of expenditures attributed to diabetes [3] . Hypertension and proteinuria are established risk factors for progression to advanced stages of kidney disease in diabetic populations [4] . Interruption of renin-angiotensin system (RAS) with angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) is indicated in patients with diabetes who present with micro-or macroalbuminuria [5] . The efficacy of RAS blockade in slowing progression of proteinuria in diabetic and non-diabetic populations is well recognized [6] [7] [8] . Nevertheless, treatment with ACE inhibitors and/or ARBs has limitations. A considerable number of patients still progress to renal failure despite being treated with maximum recommended doses of ACE inhibitors and/or ARBs. Intriguingly, the ONTARGET trial demonstrated that combination therapy with ramipril and telmisartan is associated with higher rates of serum creatinine doubling and dialysis compared with either medication used alone [9] . These impediments have provided an impetus to develop more efficacious treatment strategies. It is suggested that blockade of aldosterone as the end product of RAS provides additional benefits in terms of prevention of kidney damage by means of reducing inflammation, oxidative stress and fibrosis [10] . It seems likely that mineralocorticoid receptor blockade using aldosterone antagonists, when used in combination with ACE inhibitors and/or ARBs, lowers the risk of renal disease progression independent of blood pressure (BP)-lowering effects [11, 12] . However, randomized clinical trials in this regard have mainly evaluated the beneficial effects of addition of aldosterone blockers to ACE inhibitors, or a combination of ACE inhibitors and ARBs (i.e. triple blockade of RAS) [13] [14] [15] . To date, evidence assessing whether addition of aldosterone blockade to an ARB-based regimen offers benefits similar to those of addition to an ACE inhibitor-based or combined ACE inhibitor/ARB-based regimen is lacking. Therefore, the present randomized clinical trial was designed to evaluate the efficacy of spironolactone (SPR) plus losartan with respect to BP control, proteinuria reduction and renal function preservation in a sample of patients with type 2 diabetes and diabetic nephropathy.
S U B J E C T S A N D M E T H O D S

Subject enrollment
At the diabetes clinic of Vali-Asr hospital (Tehran, Iran), between April and December 2010, we screened 373 consecutive patients who were known cases of type 2 diabetes according to the American Diabetes Association criteria [16] . After initial assessment, 136 patients meeting the inclusion criteria were recruited. The inclusion criteria were as follows: (i) urinary albumin excretion (UAE) ≥30 mg/24 h in at least two out of three 24-h urine sample collections; (ii) taking a combination of an ACE inhibitor (enalapril) and an ARB (losartan) with recommended doses for diabetic nephropathy for at least the past year and (iii) willingness to participate in the trial. Subjects were excluded if they had non-diabetic kidney disease, known cardiovascular or liver disease, chronic kidney disease stages ≥4 and baseline serum potassium concentrations ≥5.5 meq/L. No kidney biopsies were performed to distinguish diabetic nephropathy from other causes of chronic kidney disease. Before enrollment, all subjects gave written informed consent. All interventions involving human subjects were carried out according to the principles laid down in the Declaration of Helsinki. The university's ethics committee also approved the trial protocol.
Study design
This single-center, open-label, parallel-group, randomized clinical trial is registered with ClinicalTrials.Gov (registration number NCT01667614). Using randomization software, eligible subjects were assigned to either arm of the trial. We hypothesized that the rate of loss to follow-up would be higher in the SPR/ARB arm. Therefore, an unbalanced randomization scheme was employed so that the number of allocated participants would be approximately 20% more in SPR/ARB than in the ACE/ARB arm. In the SPR/ARB arm (n = 74), enalapril was discontinued, and after a 2-week wash-out period of ACE inhibitor, a single-dose of SPR 25 mg daily was added. In the ACE inhibitor/ARB arm (n = 62), a combination of fixed dose enalapril (30-40 mg per day) and losartan (50-100 mg per day) was continued as before. Losartan dosage was comparable between the trial arms (P = 0.794). No dose adjustment for antihypertensive medications was done during the trial period.
After the baseline visit, regular follow-up visits for both groups were scheduled 3 months apart. At each visit, physical examination and laboratory assessments were conducted employing the same protocol (see below). The baseline visit of SPR/ARB patients was conducted within 1 week of stopping ACE inhibitor and before initiation of SPR. An extra visit in the SPR/ARB group was also conducted 1 month after trial initiation and measurement of serum potassium and an ECG were done to evaluate asymptomatic hyperkalemia (defined as potassium concentrations >5.5 meq/L). Before medication initiation, all of the patients were instructed about the signs and symptoms of hyperkalemia via an educational leaflet. The patients were also educated regarding the importance of limiting salt intake and restricting protein consumption to recommended daily amounts in patients with diabetic nephropathy and/or hypertension. No formal assessment about adherence to these recommendations was done during the trial.
Assessment
Before study commencement, the patients were interviewed using a pre-designed questionnaire. BP was measured using a standard mercury sphygmomanometer (Riester, Big Ben adults, Germany) with the patient in sitting position after ten minutes of resting; The average of two readings five minutes apart was recorded.
Laboratory evaluations
After an overnight 12-h fast, 10 mL of venous blood sample was collected from each participant. At baseline and follow-up visits, the patients were also instructed to collect 24-h urine samples.
Fasting plasma glucose concentrations were measured using the Glucose Oxidase Method. Fasting insulin concentrations were determined using radioimmunoassay techniques (Immunotech, Prague, Czech Republic). High-performance liquid chromatography (HPLC) was performed to assess glycated hemoglobin A1c (HbA1c). Total cholesterol was measured using enzymatic methods (Pars Azmun, Karaj, Iran). Sodium and potassium concentrations were determined using the flame photometry method. The Jaffe method was employed to assess serum creatinine (Pars Azmun, Karaj, Iran). Estimated glomerular filtration rate (eGFR) was calculated using the formula of Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) [17] . No calibration of creatinine levels to standardized reference values was done before eGFR calculation. UAE was measured by colorimetric methods using commercial kits (ZiestChem Diagnostics, Tehran, Iran).
Statistical analysis
Continuous variables with normal distribution are expressed as mean ± standard deviation (SD) and categorical variables as proportions or ratios. Distribution of UAE values did not comply with the assumption of normality and logarithmic transformation was necessary to correct right-sided skewness. In all analyses log-transformed values were used instead. UAE values are presented as median (interquartile range). The baseline characteristics of the study participants were compared using independent t-test or chi square, where appropriate. The baseline characteristics of patients who completed the study and those who were lost to follow-up were also compared to evaluate whether loss to follow-up occurred at random. Within-group changes of outcome variables after 12 and 18 months were assessed using paired t-test. Comparative efficacy of interventions in short term (3 months), medium term (12 months) and long term (18 months) was determined using mixed between-within analysis of variance (ANOVA) method. In each analysis, effect size was calculated from partial eta squared (based on Cohen's recommendations: 1% small effect, 6% medium effect, 13.8% large effect). Visit-to-visit changes in outcome variables were examined by post hoc analysis using the Tukey's least significant difference (LSD) method. Additionally, mixed between-within ANOVA models, with mean SBP and DBP introduced as covariate, were constructed to assess whether the observed differences between two interventions with respect to parameters of kidney function are confounded by changes in BP over the trial period. All statistical analyses were performed using SPSS version 19.0 (IBM Corporation, New York, United States). A P-value of <0.05 was considered statistically significant.
R E S U LT S
One hundred and thirty-six patients met the inclusion criteria and were allocated to either the SPR/ARB or the ACE inhibitor/ARB arm of the trial ( Figure 1 ). All patients completed a 3-month follow-up. A total of 114 patients returned for the 12-month visit (16.2% were excluded or lost to follow-up). Finally, 18 months after trial initiation, the 97 remaining patients were evaluated.
A comparison of clinical and demographic variables of patients who completed the trial and those lost to follow-up at either the 12th or the 18th month can be found in Supplementary data, Table S1 .
Baseline clinical and demographic data for each arm of the trial are provided in Table 1 . Fifty-five percent of the patients in the SPR/ARB group and 62% of ACE/ARB subjects were previously diagnosed with hypertension. In addition to enalapril and losartan, 25 patients in the SPR/ARB group and 21 patients in the ACE/ARB group were also taking beta blockers (atenolol or metoprolol). Moreover, six SPR/ARB and seven ACE/ARB patients also took diltiazem or amlodipine for BP control. Baseline UAE ranged from 31.0 to 2900.00 mg/24 h. Baseline eGFR ranged from 31.26 to 109.66 mL/min/1.73 m 2 . Baseline values of all target variables including SBP, DBP, UAE, serum creatinine and eGFR were similar between the two groups ( Table 1) .
Mean changes in target variables in the SPR/ARB and ACE/ARB groups are presented in Table 2 .
Within-group changes in SPR/ARB SBP and DBP significantly decreased after 18 months (P = 0.014 and 0.019, respectively). This was accompanied by a significant decline in UAE (P < 0.001). Additionally, eGFR significantly declined over the study period (P = 0.003). During the trial period, an average increase of 0.2 meq/L in potassium concentrations was noted (K = 4.44 ± 0.45 meq/L at baseline and 4.65 ± 0.54 meq/L at the 18th month). In three patients, SPR was discontinued because of asymptomatic hyperkalemia. After SPR discontinuation, all the three patients were followed up and potassium levels returned to normal values within 6 months. Of note, all of the patients experienced a significant rise in UAE values after SPR discontinuation (438.0, 36.0, 177.0 versus 1517.5, 259.0, 1127.5 mg/24 h).
Within-group changes in ACE inhibitor/ARB Continuation of ACE/ARB over the course of 18 months did not significantly change SBP, DBP, UAE or serum creatinine (Table 2) . On the other hand, patients experienced a significant decline in eGFR by the end of trial (P = 0.013).
Comparative efficacy of interventions
Comparative efficacy of two treatment strategies in reduction of target variables is delineated in Table 3 . SBP decreased more significantly in SPR/ARB group compared with F I G U R E 1 : Recruitment, randomization and follow-up of patients. Between April and December 2010, 373 type 2 diabetes patients were screened. One hundred and thirty-six patients were eligible and were randomly allocated to trial arms. Patients were followed up regularly every 3 months for up to 18 months and the trial was completed in May 2012. Intervention in three patients in the SPR/ARB group was discontinued due to laboratory abnormalities in serum potassium. Another patient was asked to stop taking SPR due to bothersome gynecomastia. Main reasons for discontinued intervention as stated by patients included (i) personal issues; (ii) financial restraints keeping them from frequent travel to Tehran in those not residing in the capital and (iii) Preferring receiving care from the private sector rather than a teaching hospital. Abbreviations: SPR, spironolactone; ARB, angiotensin II receptor blocker; ACE inhibitor, angiotensin-converting enzyme inhibitor.
ACE inhibitor/ARB after 3, 12 and 18 months (P = 0.009, 0.001 and <0.001, respectively). A gradual increasing trend in effect size was noted; while addition of SPR generated a small effect in SBP reduction, it grew to medium and large effect sizes at 12 and 18 months, respectively (Table 3) . SPR/ARB was superior to ACE inhibitor/ARB in reduction of DBP after 
O R I G I N A L A R T I C L E
S p i r o n o l a c t o n e a n d p r o t e i n u r i a 12 and 18 months, but not after 3 months (P = 0.129, 0.046 and 0.001, respectively). While UAE reduction was comparable between the two groups after 3 months, SPR/ARB performed significantly better after 12 and 18 months (P = 0.031 and 0.017, respectively). It is conceivable that UAE reduction in the SPR/ARB group is confounded by the concomitant reduction in SBP and DBP. However, after adjustment for mean SBP and DBP over the trial period, SPR/ARB was still significantly more effective (P = 0.042, effect size: 4.33% for 12 months and P = 0.038, effect size: 7.0% for 18 months), suggesting that the UAE reduction by SPR cannot be solely attributed to concomitant reduction in BP. Moreover, as evident in Figure 2 , UAE in SPR/ARB group reached a nadir at around the 9th month, and it was relatively sustained thereafter. Post hoc analysis replicated the same; while UAE change from baseline to the 9th month was statistically significant (P = 0.006), it did not change considerably from the 9th to the 18th months (P = 0.381).
Neither intervention proved to be superior in preventing creatinine increase or eGFR decline after three, 12 or 18 months (Table 3) . Similar findings were replicated after controlling for the effect of mean SBP and DBP (data not shown). Post hoc analysis of eGFR revealed a significant decline of 3.5 mL/min/1.73 m 2 3 months after trial initiation (P = 0.015 for baseline to third month). After that, patients 
A. Esteghamati et al. Abbreviations: SPR/ARB, spironolactone + angiotensin II receptor blocker; ACE inhibitor/ARB, angiotensin-converting enzyme inhibitor + angiotensin II receptor blocker; UAE, urinary albumin excretion; SBP, systolic blood pressure; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate.
S p i r o n o l a c t o n e a n d p r o t e i n u r i a F I G U R E 2 : Mean changes in outcome variables over the trial course (18 months, seven visits). Variables are presented as mean ± standard error. For UAE, log-transformed values are presented. P-values for between-group comparisons: systolic blood pressure (P < 0.001); diastolic blood pressure (P = 0.001); urinary albumin excretion (P = 0.017); serum creatinine (P = 0.802); estimated glomerular filtration rate (P = 0.674). Abbreviations: SPR, spironolactone; ARB, angiotensin II receptor blocker; ACE inhibitor, angiotensin-converting enzyme inhibitor.
in the SPR/ARB group experienced an indolent but progressive decline in eGFR. Similar analyses for ACE inhibitor/ARB group revealed no significant difference in visit-to-visit decline of eGFR (P > 0.05 for all tests). Overall, the monthly decline rate of eGFR was 0.441 and 0.410 mL/min/1.73 m 2 in SPR/ARB and ACE inhibitor/ARB, respectively. To assess whether the decline rate between groups would be different if the early drop in SPR/ARB group is ignored, the analysis was repeated with treating the third-month values as baseline. Again, between-group comparison indicated no significant difference (F = 0.099, P = 0.755).
D I S C U S S I O N
In the present study, replacement of enalapril with SPR proved to be significantly more effective than continuation of dual RAS blockade in reduction of both SBP and DBP over a follow-up period of 18 months (9 mmHg in SBP and 5 mmHg in DBP). Rossing and colleagues (2005) found a significant reduction of about 10 mmHg in SBP and 5 mmHg in DBP after addition of SPR 25 mg daily in 21 type 2 diabetes patients [15] . Contrary to these observations, some have reported that SPR at the doses used for proteinuria reduction does not affect BP [18, 19] . Differences in the patients recruited with respect to baseline kidney function, pre-existing hypertension and previous anti-hypertensive treatments are likely to underline this discrepancy. In our sample, more than half of the participants were already diagnosed with hypertension, and more than two-thirds had baseline BP values higher than 130/80. In a systematic review of SPR trials (2008), it was shown that five out of six trials that reported a significant drop in BP enrolled subjects with initial values of greater than 130/80 mmHg [20] .
Herein, SPR/ARB reduced UAE independent of SBP and DBP. In a randomized trial of 165 patients with chronic glomerulonephritis of idiopathic origin already treated with ACE inhibitor and/or ARB, addition of SPR 25 mg daily significantly abated albuminuria by 58% after 12 months [13] . In another trial of 81 type 2 diabetes patients, addition of SPR 25 mg daily was more effective than addition of losartan (100 mg daily) to a maximally dosed ACE inhibitor regimen [21] . Similar results have been replicated using either SPR or eplerenone in diabetic populations [22] [23] [24] .
In patients taking SPR/ARB, the steepest decline in UAE was observed in the first 3 months. Congruently, in an 8-week trial of SPR in 42 patients with chronic kidney disease, 75% of antiproteinuric effects of SPR were apparent 2 weeks after trial initiation [25] . It seems that there is an early 'kick-start' in SPR effects on glomerular filtration of proteins; the proteinuria is then sustained. It is unclear, however, for how long this beneficial effect is prolonged since the majority of studies in this regard have followed patients for no longer than 12 months. To our knowledge, our study is among the first to extend the follow-up duration of patients to up to 18 months. Our results point to a possible long-term benefit for SPR in UAE diminution, since albuminuria was maintained and did not return to baseline values by the end of trial.
Here, a progressive decline in eGFR concentrations was observed in both groups, and the between-group difference did not reach statistical significance (about 9 mL/min/1.73 m 2 in SPR/ARB group and 8 mL/min/1.73 m 2 in ACE inhibitor/ ARB group). Moreover, it persisted even after adjustment for SBP and DBP. SPR initiation resulted in a sudden and significant decline in eGFR of about 4 mL/min/1.73 m 2 after 3 months. A similar observation has been made by other research groups [15, 26] . Bianchi and colleagues reported a significant drop of about 5 mL/min/1.73 m 2 as early as 4 weeks after SPR was added, followed by a stable rate of monthly decline (0.323 versus 0.474 in case and control groups, respectively, P < 0.01) [13] . This was not the case in our study, however. Our analyses confirmed that even if the early eGFR changes in the SPR/ARB group is disregarded, SPR does not offer additional renoprotection with respect to eGFR decline. Similar initial drops have been reported with both captopril and irbesartan [27, 28] . While mechanisms underlying this early decline remain obscure for the most part, it is likely that hemodynamic alterations caused by suppression of genomic effects of aldosterone contribute to this phenomenon [13, 26] .
Asymptomatic hyperkalemia occurred in only three patients in our trial (3.6%) and resolved soon after SPR discontinuation. Hyperkalemia is a major limiting factor in administration of aldosterone antagonists and, if left undetected, could lead to significant mortality and morbidity [29, 30] . However, our results demonstrated that the addition of SPR to ARB is relatively safe, mostly due to well-preserved renal function of trial participants (mean baseline eGFR in patients with hyperkalemia was 74 mL/ min/1.73 m 2 ). In line with previous reports [26, 29] , in our sample, hyperkalemia occurred in patients who were older and had higher baseline potassium concentrations. Therefore, frequent assessment of serum potassium in patients with elevated potassium due to prior treatment with ACE inhibitors and/or ARBs, advanced age and diminished GFR is advisable.
The detrimental effects of aldosterone are not adequately arrested by the use of ACE inhibitor, ARB or a combination of both [31] , and aldosterone escape might play an important role in this regard [32] . It is believed that aldosterone escape occurs quite commonly with reports indicating prevalence rates as high as 22% with ARBs [32] and 40% with ACE inhibitors [33] . Treatment of aldosterone escape with SPR has been effective in reduction of proteinuria [32] . Hence, it is plausible that additional blockade of aldosterone-via mineralocorticoid receptor antagonists-may result in more efficacious blockade of the RAAS system. It is suggested that low doses of SPR exert antiproteinuric effects mainly via the non-genomic pathway; our findings, along with a number of previous reports, indicate that these effects are indeed independent of BP control [14, [34] [35] [36] . Non-genomic effects of aldosterone may involve inflammation, oxidative stress, endothelial dysfunction and subsequent apoptosis and fibrosis in podocytes [10, [37] [38] [39] .
A number of limitations in our study should be considered. First, during the course of the trial, a relatively high rate of loss to follow-up was observed. Nevertheless, comparison of the baseline characteristics of patients who completed the study and who were lost to follow-up at the 12th and the 18th months revealed no significant differences between the two groups. This finding supports the notion that dropout of patients has occurred at random. Second, the present study was an open-label trial and no placebo-control was carried out. This might have contributed to potential bias in the assessment of patients. Despite these limitations, our study is unique in the sense that for the first time, it examines the effects of combined SPR/losartan regimen on diabetic nephropathy, and extends the duration of follow-up beyond that in previous reports. Based on our findings, addition of SPR to an ARB-based regimen provides additional benefits with respect to BP control and proteinuria diminution. However, beneficial effects of SPR on UAE reduction should be interpreted with caution, since aldosterone blockade does not slow the progression of eGFR loss during the 18 months of trial. Nevertheless, it should be noted that there is ample evidence indicating that reduction of microalbuminuria per se offers renoprotection in diabetic nephropathy [28, 40] . On the other hand, sustained BP-lowering effects of SPR also contributes to preservation of renal function in patients with diabetes and hypertension [41] [42] [43] [44] . What remains to be elucidated is whether observed improvements with SPR does in fact prevent hard outcomes including cardiovascular events, creatinine doubling, progression to ESRD and need for temporary or permanent dialysis. Future large multicenter RCTs with eventbased outcomes and longer durations of follow-up are paramount to evaluate long-term effects of reduced proteinuria by SPR on eGFR preservation.
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